Bank of America Lowers Kenvue (NYSE:KVUE) Price Target to $25.00

Kenvue (NYSE:KVUE - Get Free Report) had its price objective lowered by stock analysts at Bank of America from $27.00 to $25.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Bank of America's target price would indicate a potential upside of 16.80% from the stock's current price.

Other research analysts also recently issued research reports about the stock. UBS Group boosted their target price on shares of Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Friday, May 9th. Evercore ISI assumed coverage on shares of Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price on the stock. Barclays boosted their target price on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Redburn Atlantic assumed coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price on the stock. Finally, Citigroup reiterated a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $24.88.

Kenvue Trading Down 1.9%

Shares of NYSE:KVUE traded down $0.42 during trading on Tuesday, reaching $21.41. The stock had a trading volume of 30,739,547 shares, compared to its average volume of 16,307,340. The firm's fifty day moving average is $22.26 and its 200 day moving average is $22.29. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. Kenvue has a 52 week low of $17.85 and a 52 week high of $25.17. The stock has a market cap of $41.07 billion, a price-to-earnings ratio of 19.84, a P/E/G ratio of 3.39 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. During the same period in the prior year, the firm posted $0.28 EPS. The company's quarterly revenue was down 3.9% on a year-over-year basis. As a group, equities analysts forecast that Kenvue will post 1.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Kenvue

Institutional investors and hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD increased its stake in Kenvue by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock valued at $5,249,665,000 after buying an additional 8,211,748 shares during the last quarter. Vanguard Group Inc. increased its stake in Kenvue by 4.9% in the 1st quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company's stock valued at $5,494,882,000 after buying an additional 10,600,682 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after buying an additional 10,682,003 shares during the last quarter. Geode Capital Management LLC increased its stake in Kenvue by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock valued at $980,989,000 after buying an additional 1,391,854 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after buying an additional 16,269,721 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.